Ge Li Pharmaceutical - B(01672.HK) major shareholder made a voluntary lock-up commitment 🔒

TopEscapeArtist · 2025-10-05T19:58:09+00:00

The controlling shareholder of GeLi Pharmaceutical, Wu Jinzi, and his wife He Jingdao recently announced a voluntary lock-up commitment, stating that they will not sell or stake their held shares, totaling approximately 576 million shares, demonstrating their confidence in the company's prospects. This move is related to the timing of the release of three clinical data, which may enhance market interest in the company.

TopEscapeArtist

2025-10-05 19:58:09

Abstract generation in progress

The major shareholders of Ge Li Pharmaceutical Holdings have recently shown a considerable level of confidence in the company's prospects. 🚀 The founder Wu Jinzi and his wife He Jingshao suddenly announced a voluntary lock-up commitment. No selling of shares. No staking of shares. This commitment covers all the company stocks they hold directly or indirectly.

This decision seems to be related to the release of three important clinical data points:

Data from the U.S. Phase I clinical study of ASC47 combined with Semaglutide in obese populations is expected to be released by the end of October 2025. 🧪
Results of the ASC30 oral tablet for the treatment of obesity or overweight in a 13-week Phase IIa study in the United States. Expected to be published in December 2025.💊
ASC50 Phase I single-dose study data in healthy populations. The time point is similar, also in December 2025. 🔬

The numbers look impressive. The Wu Jinzhi couple holds about 576 million restricted shares. This is approximately 58.03% of the company's shares! 💼 Quite rare. The controlling shareholders doing this reflects, to some extent, their expectations for the company's future. 🌕

Voluntary selling prohibitions in the Web3 and biotechnology sectors seem to be becoming more common. Investors usually see this as a signal that the management is optimistic about the company. 📈 As these clinical data continue to be released one after another, interest in Gilead Sciences may become even stronger. Looking forward to seeing the results. 🔥

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.